Avinger has announced that the company received 510(k) clearance from the US Food & Drug Administration (FDA) for its Pantheris SV (small vessel) image-guided atherectomy system.
Avinger is a developer of image-guided, catheter-based systems for the diagnosis and treatment of patients with peripheral arterial disease (PAD). Pantheris SV, a product line extension of the company’s Lumivascular image-guided atherectomy platform, is expected to expand the available market for the product line by up to 50% and allow the company to address a larger portion of the estimated US$500 million atherectomy market. Designed with a lower profile and longer length than Pantheris, the small vessel device is indicated for the diagnosis and treatment of PAD in small vessels (2mm–4mm in diameter). The new device incorporates key improvements introduced to the platform with the launch of the next-generation Pantheris system in June 2018, including a stiffer shaft for increased pushability, a refined OCT imaging system, and an enhanced cutter design.
Pantheris SV received CE Marking in October 2018 and the first patients were treated with the device in Germany in November. The company intends to initiate a limited launch of the device in several sites in the USA when commercial product is available. Distribution is expected to be expanded as the company gains additional clinical experience, builds product inventory, and receives purchasing approvals in new Lumivascular sites.
“We are excited to receive US pre-marketing clearance for Pantheris SV, which we believe could expand our addressable market for atherectomy procedures by as much as 50%,” says Jeff Soinski, Avinger’s president and CEO. “With the clearance of this new device, we are well-positioned to build on the positive momentum we have seen in our Pantheris business since the introduction of the next-generation system in 2018. Following our anticipated limited launch, we plan on leveraging our growing commercial infrastructure and installed base of Lumivascular accounts to efficiently scale up the introduction of Pantheris SV and drive growth of the product family in the second half of 2019.”
Jaafer Golzar, Avinger’s chief medical officer and a highly experienced interventionalist treating patients with small vessel disease, comments, “This product line extension represents a significant advancement for patients with PAD, in particular those suffering from the complications of small vessel disease. Treating small vessels presents a number of challenges and physicians have had a limited set of minimally invasive tools that can provide safe and effective outcomes for this high-risk patient population. Pantheris SV uses a combination of directional atherectomy with onboard image-guidance to provide several potential clinical advantages, including an enhanced safety profile, the ability to maximise luminal gain without causing vascular injury, and precise vessel measurement capabilities.”
Atherectomy is a minimally invasive treatment for PAD in which a catheter-based device is used to remove plaque from a blood vessel. Lumivascular technology allows physicians, for the first time ever, to see from inside the artery during an atherectomy procedure by using an imaging modality called optical coherence tomography, or OCT, that is displayed on Avinger’s proprietary Lightbox console. Physicians performing atherectomy with other devices must rely solely on X-ray as well as tactile feedback to guide their interventions while treating complicated arterial disease. With the Lumivascular approach, physicians can more accurately navigate their devices and treat PAD lesions, thanks to the real-time OCT images generated from inside the artery, without exposing healthcare workers and patients to the negative effects of ionising radiation.
Duc Tin clinic
Tin tức liên quan
NICE Endorses PICO negative pressure wound dressings for closed surgical incisions
Tack Endovascular System launches in USA, first commercial use announced
EVAR with an iliac branch endoprothesis is safe and effective
Medtronic revises IN.PACT post-market study data due to programming error, but conclusions remain the same
New DVT device completes first-in-human trial
Phone: (028) 3981 2678
Mobile: 0903 839 878 - 0909 384 389